Amit Patel, Senior Vice President
of North American Generics
The purpose of Dr. Reddy’s North American Generics operation is to provide affordable and innovative medicines for healthier lives. Dr. Reddy’s North American Generics understands and appreciates that every “customer” of pharmaceutical products—the purchasing wholesaler/ chain/retailer/pharmacy, the prescribing physician, the patient, and the payer— has a “choice.” They have a choice of products, as well as a choice of where to acquire those products. Knowing this, we strive daily to provide the best products at the most competitive prices.
Established in 2001,Dr. Reddy’s North American Generics began marketing its finished dosage-form products in the United States and Canada. Under the Dr. Reddy’s label, the company currently markets 38 prescription products in 170 dosing presentations (ie, strengths and package sizes). In addition, Dr. Reddy’s Private Label OTC Group, which was established in 2007, markets 13 different products in 187 packaging presentations.
Aggressive Product Pipeline
The generics company has an aggressive product pipeline— with many products under development and awaiting FDA approval. To start 2010, Dr. Reddy’s received approvals for Fluoxetine 90 mg (Prozac Weekly; Eli Lilly), Amlodipine Besylate and Benazepril (Lotrel; Novartis), and Tacrolimus (Prograf; Astellas). In the prior 12 months, Dr. Reddy’s has launched the following important prescription generic products: Allopurinol (Zyloprim; Prometheus Inc), Risperidone ODT 1 mg, 3 mg, and 4 mg (Risperdal M-Tab; Janssen), Cetirizine Syrup (Zyrtec; Pfizer Inc), Risperidone Solution (Risperdal Solution; Janssen), Ranitidine Syrup (Zantac; GlaxoSmithKline), Glyburide Metformin (Glucovance; Bristol-Myers Squibb), and Nateglinide (Starlix; Novartis). We have also brought to the market generic OTC products—most recently Omeprazole Magnesium 20.6-mg Capsules (Prilosec OTC; AstraZeneca AB). The OTC group is positioned uniquely to support Rx-to-OTC switches.
Dr. Reddy’s North American Generics is vertically integrated— from process development of active pharmaceutical ingredients (APIs), to formulations and the submissions of abbreviated new drug applications, to manufacturing of finished dosages on over 90% of our products, allowing them to compete in a marketplace that has increasing price pressure and multiple competitors.
Our modern, cutting-edge technology facilities, which have an enviable record of regulatory compliance, follow cGMP guidelines in the production of finished dosage forms.
Dr. Reddy’s announced plans including the future expansion of the company’s manufacturing facility in Shreveport, Louisiana. The facility manufactures solid, semisolid, and liquid dosage forms. The future will see Dr. Reddy’s expand into additional dosage forms, including injectables, liquids, and biologicals, as well as topicals.
Dr. Reddy’s strives consistently to be the “first choice” for our customers, whomever they may be, by leveraging the company’s vertical integration—from the process development of APIs to finished dosage forms. The Sales, Marketing, Regulatory, Sales Operations, and Supply Chain teams at Dr. Reddy’s North American Generics possess proven expertise, and they are ready to take the company to the next level. PT
For more information, visit www.drreddys.com.